cold-like symptoms, like sore throat and congestion; cold-like symptoms, like sore throat and congestion; Received two doses of Rabavert and one dose of another brand that they had in stock; Case reference number US-BN-2022-001075 is a spontaneous case report initially received on 12-May-2022 from a consumer via Communication (reference number: USBAV22-0181) and concerns a male patient of unspecified age.  The patient's medical history and concomitant medication details were not provided.  On unspecified day, the patient was vaccinated with the first dose of RabAvert (Rabies Virus (Inactivated, Strain Flury LEP) (PCEC)); batch number: unknown) at a dose reported as 2.5 international units, administered intramuscularly, at unknown site of administration, for post-exposure prophylaxis due to a bat bite. As reported, the patient received the immune globulin as well.  On unspecified day, an unknown amount of time after the first dose, the patient was vaccinated with the second dose of RabAvert (batch number: unknown) at a dose reported as 2.5 international units, administered intramuscularly, at unknown site of administration.  On unspecified day, an unknown amount of time after the first dose, the patient was vaccinated with a dose of Rabies vaccine (brand name unknown, as reported other brand name) at an unknown dose, route or site of administration (explicitly coded as 'Interchange of vaccine products'), for post-exposure prophylaxis due to a bat bite.  On unspecified date, an unknown amount of time after the first dose, the patient was vaccinated with the third dose of Rabavert (batch number: unknown) at a dose reported as 2.5 international units, administered intramuscularly, at unknown site of administration.  *On an unspecified date, three weeks after vaccination with the rabies vaccine (as reported), the patient experienced cold-like symptoms like sore throat and congestion.*  *At the time of this report the outcome of the events was unknown.*  *The reporter assessed the events of cold-like symptoms, like sore throat and congestion as non-serious and as possibly related to RabAvert vaccination.*  Additional information received from Communication on 13-May-2022 included vaccination details for two doses of Rabavert and additional co-suspect vaccine.  Additional information received from Communication on 16-May-2022 included third dose of Rabavert.  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow-up information received from Communications on 07-Jun-2022 included additional events.  Additional information received from Communication on 08-Jun-2022 included local case ID.  This case is linked with cases no. US-BN-2022-001076, US-BN-2022-001077, US-BN-2022-001090 (the same reporter).; Reporter's Comments: A male patient of unspecified age was vaccinated with a dose of Rabies vaccine (brand name unknown, as reported other brand name) after the patient received 2 doses of Rabavert for post-exposure prophylaxis due to a bat bite, which is considered as interchange of vaccine products. Reportedly, on unspecified date, an unknown amount of time after the first dose, the patient was vaccinated with the third dose of Rabavert, and on an unspecified date, three weeks after the vaccination with the rabies vaccine (as reported), the patient experienced non-serious events of cold-like symptoms like sore throat and congestion. Oropharyngeal pain and nasal congestion are not listed for RabAvert according to the guidelines, whilst interchange of vaccine products is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. The patient's co-suspect vaccination confounded the causality for the events. However, since the contributory role of the suspect vaccine cannot be excluded with certainty, the events of oropharyngeal pain and nasal congestion have been considered as related to RabAvert. Interchange of vaccine products has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age was vaccinated with a dose of Rabies vaccine (brand name unknown, as reported other brand name) after the patient received 2 doses of Rabavert for post-exposure prophylaxis due to a bat bite, which is considered as interchange of vaccine products. Reportedly, on unspecified date, an unknown amount of time after the first dose, the patient was vaccinated with the third dose of Rabavert, and on an unspecified date, three weeks after the vaccination with the rabies vaccine (as reported), the patient experienced non-serious events of cold-like symptoms like sore throat and congestion. Oropharyngeal pain and nasal congestion are not listed for RabAvert according to the guidelines, whilst interchange of vaccine products is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. The patient's co-suspect vaccination confounded the causality for the events. However, since the contributory role of the suspect vaccine cannot be excluded with certainty, the events of oropharyngeal pain and nasal congestion have been considered as related to RabAvert. Interchange of vaccine products has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.